Amendments To The Claims

The listing of claims will replace all prior versions, and listings, of the claims in the application.

Listing Of Claims:

Claim 1 (Currently amended) A compound of [the general] formula (I):

B1



(I)

wherein

R^1, R^2, R^3 and R^4 independently are hydrogen, halogen, [-CN,] $-CF_3$[,] or $-NO_2$, [$-OR^5$, lower alkyl, $-SR^5$, $-S(O)_2NR^5R^6$, $-S(O)NR^5R^6$, $-S(O)_2R^5$, $-S(O)R^5$, $-C(O)NR^5R^6$, $-CH_2OR^5$, $-CH_2NR^5R^6$, $-NR^5R^6$, $-C(O)R^5$ or $-C(O)OR^5$,

wherein R^5 and R^6 independently are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, heteroaryl-lower alkenyl or heteroaryl-lower alkynyl, or R^5 and R^6 together with the nitrogen atom to which they are bound form a 3 to 8 membered heterocyclic ring optionally containing one or more further heteroatoms selected from nitrogen, oxygen and sulfur and optionally containing one or more double bonds,

in which the cycloalkyl, cycloalkenyl, heterocyclyl, aryl and heteroaryl rings may optionally be substituted with one or more substituents independently selected from halogen, lower alkyl, lower alkanoyl, -OH, $-CH_2OH$, $-NO_2$, -CN, -C(O)OH, -O-lower alkyl, $-C(O)OCH_3$, $-C(O)NH_2$, $-OCH_2C(O)NH_2$, $-NH_2$, $-N(CH_3)_2$, $-CH_2N(CH_3)_2$, $-SO_2NH_2$, $-OCHF_2$, $-CF_3$ and $-OCF_3$,

one of] X and V [is] are =N-, [and the other is =CD- or =N-,

wherein D is hydrogen, halogen, -CN, $-CF_3$, $-NO_2$, $-OR^7$, $-NR^7R^8$, lower alkyl, aryl, $-C(O)NR^7R^8$, $-CH_2OR^7$, $-CH_2NR^7R^8$ or $-C(O)OR^7$,

B1

wherein R^7 and R^8 independently are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, heteroaryl-lower alkenyl or heteroaryl-lower alkynyl, or R^7 and R^8 together with the nitrogen atom to which they are bound form a 3 to 8 membered heterocyclic ring optionally containing one or more further heteroatoms selected from nitrogen, oxygen and sulfur and optionally containing one or more double bonds,

in which the cycloalkyl, cycloalkenyl, heterocyclyl, aryl and heteroaryl rings may optionally be substituted with one or more substituents independently selected from halogen, lower alkyl, lower alkanoyl, -OH, $-CH_2OH$, $-NO_2$, -CN, -C(O)OH, -O-lower alkyl, $-C(O)OCH_3$, $-C(O)NH_2$, $-OCH_2C(O)NH_2$, $-NH_2$, $-N(CH_3)_2$, $-CH_2N(CH_3)_2$, $-SO_2NH_2$, $-OCHF_2$, $-CF_3$ and $-OCF_3$,

L and M independently are a valence bond, $-(CH_2)_mS(CH_2)_n-$, $-(CH_2)_mO(CH_2)_n-$, $-(CH_2)_mS(O)(CH_2)_n-$, $-(CH_2)_mS(O)_2(CH_2)_n-$, $-(CH_2)_mCH=CH(CH_2)_n-$, $-(CH_2)_mC\equiv C(CH_2)_n-$, $-(CH_2)_mCHR^9(CH_2)_n-$, $-(CH_2)_mNR^9(CH_2)_n-$, $-(CH_2)_mC(O)NR^9(CH_2)_n-$, $-(CH_2)_mC(O)O(CH_2)_n-$, $-S(CH_2)_mC(O)O(CH_2)_n-$, $-S(O)_2(CH_2)_mC(O)O(CH_2)_n-$, $-S(O)_2(CH_2)_mC(O)(CH_2)_n-$, $-S(O)_2NR^9(CH_2)_mC(O)O(CH_2)_n-$, $-S(CH_2)_mC(O)NR^9(CH_2)_n-$, $-(CH_2)_mOC(O)(CH_2)_n-$, $-(CH_2)_mC(O)(CH_2)_n-$, $-(CH_2)_mC(NOR^9)(CH_2)_n-$, $-(CH_2)_mNR^9S(O)_2(CH_2)_n-$, $-(CH_2)_mS(O)_2NR^9(CH_2)_n-$, $-(CH_2)_mCHOR^9(CH_2)_n-$, $-(CH_2)_mP(O)(OR^9)O(CH_2)_n-$, $-S(O)_2(CH_2)_mCONR^9(CH_2)_n-$, $-S(O)_2(CH_2)_mOC(O)NR^9(CH_2)_nC(O)O(CH_2)_r-$, $-NR^9O(CH_2)_n-$, $-NR^9NR^{9a}C(O)NR^{9b}(CH_2)_n-$, $-NR^9(CH_2)_mNR^{9a}C(O)(CH_2)_n-$ or $-NR^9(CR^{9c}R^{9d})_n-$,]

<u>L is $-SO_2-CH_2-$, -S-, -SH, $-NH_2$ or -NH-,</u>

<u>M is $-NR^9-CH_2$, $-SO_2$-alkylene, -S-alkylene, -SO-alkylene, -NH-, $-NH_2$ or a valence bond,</u>

wherein R^9[, R^{9a} and R^{9b} independently are] <u>is</u> hydrogen, lower alkyl, [lower alkenyl, lower alkynyl,] cycloalkyl[, cycloalkenyl, aryl, heterocyclyl,] <u>or</u> heteroaryl, [cycloalkyl-lower alkyl, cycloalkyl-lower

alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, heteroaryl-lower alkenyl or heteroaryl-lower alkynyl,]

in which the cycloalkyl[, cycloalkenyl, heterocyclyl, aryl] and heteroaryl rings may optionally be substituted with one or more substituents independently selected from halogen, lower alkyl, lower alkanoyl, -OH, $-CH_2OH$, $-NO_2$, -CN, -C(O)OH, -O-lower alkyl, $-C(O)OCH_3$, $-C(O)NH_2$, $-OCH_2C(O)NH_2$, $-NH_2$, $-N(CH_3)_2$, $-CH_2N(CH_3)_2$, $-SO_2NH_2$, $-OCHF_2$, $-CF_3$ and $-OCF_3$,

[R^{9c} and R^{9d} independently are hydrogen or lower alkyl,

m, n and r independently are 0, 1, 2, 3 or 4,]

A and B independently are hydrogen[, halogen, $-CF_3$, $-CF_2CF_3$, -CN, $-NO_2$,] or lower alkyl, [lower alkenyl, lower alkynyl, cycloalkyl, hydroxy,

in which the cycloalkyl ring may optionally be substituted with one or more substituents independently selected from halogen, lower alkyl, lower alkanoyl, -OH, $-CH_2OH$, $-NO_2$, -CN, -C(O)OH, -O-lower alkyl, $-C(O)OCH_3$, $-C(O)NH_2$, $-OCH_2C(O)NH_2$, $-NH_2$, $-N(CH_3)_2$, $-CH_2N(CH_3)_2$, $-SO_2NH_2$, $-OCHF_2$, $-CF_3$ and $-OCF_3$,

or A and B independently are

 ,  ,  ,  ,  ,

 ,  ,  ,  ,  ,

 ,  ,  or 

wherein

p is 1, 2 or 3,

X' is -N= or -CR^{14}=,

Y' is -N= or -CR^{15}=,

Z' is -N= or -CR^{16}=,

V' is -N= or -CR^{17}=,

W' is -N= or -CR^{18}=,

G is -$CR^{18a}R^{18b}$-, -N^+O^--, -NR^{19}-, -O- or -S-,

K is -$CR^{18c}R^{18d}$-, -NR^{20}, -O- or -S-,

B1

R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{18a}, R^{18b}, R^{18c} and R^{18d} independently are hydrogen, halogen, -CN, $-CF_3$, $-OCF_3$, $-OCH_2CF_3$, $-OCF_2CHF_2$, $-NO_2$, $-OR^{21}$, $-NR^{21}R^{22}$, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, heteroaryl-lower alkenyl or heteroaryl-lower alkynyl, $-SCF_3$, $-SR^{21}$, $-CHF_2$, $-OCHF_2$, $-OS(O)_2CF_3$, $-OS(O)_2R^{21}$, $-NR^{21}S(O)_2R^{22}$, $-S(O)_2NR^{21}R^{22}$, $-S(O)NR^{21}R^{22}$, $-S(O)_2R^{21}$, $-S(O)R^{21}$, $-CH_2C(O)NR^{21}R^{22}$, $-OCH_2C(O)NR^{21}R^{22}$, $-CH_2OR^{21}$, $-CH_2NR^{21}R^{22}$, $-OC(O)R^{21}$, $-S(O)_2NR^{21}(CH)_sC(O)OR^{22}$, $-C(O)NR^{21}(CH)_sC(O)OR^{22}$ or $-C(O)NR^{21}R^{22}$ where R^{12} and R^{13} furthermore independently may represent oxo, or two of the groups R^{10} to R^{18d} when defined in the same ring together may form a bridge $-O(CH_2)_qO-$ or $-CH_2O(CH_2)_qO-$,

in which the cycloalkyl, cycloalkenyl, heterocyclyl, aryl and heteroaryl rings may optionally be substituted with one or more substituents independently selected from halogen, lower alkyl, lower alkanoyl, -OH, $-CH_2OH$, $-NO_2$, -CN, -C(O)OH, -O-lower alkyl, $-C(O)OCH_3$, $-C(O)NH_2$, $-OCH_2C(O)NH_2$, $-NH_2$, $-N(CH_3)_2$, $-CH_2N(CH_3)_2$, $-SO_2NH_2$, $-OCHF_2$, $-CF_3$ and $-OCF_3$,

wherein R^{21} and R^{22} independently are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, heteroaryl-lower alkenyl or heteroaryl-lower alkynyl, or R^{21} and R^{22} together with the nitrogen atom to which they are bound form a 3 to 8 membered heterocyclic ring optionally containing one or more further heteroatoms selected from nitrogen, oxygen and sulfur and optionally containing one or more double bonds,

in which the cycloalkyl, cycloalkenyl, heterocyclyl, aryl and heteroaryl rings may optionally be substituted with one or more substituents independently selected from halogen, lower alkyl, lower alkanoyl, -OH, $-CH_2OH$, $-NO_2$, -CN, -C(O)OH, -O-lower alkyl, $-C(O)OCH_3$, $-C(O)NH_2$, $-OCH_2C(O)NH_2$, $-NH_2$, $-N(CH_3)_2$, $-CH_2N(CH_3)_2$, $-SO_2NH_2$, $-OCHF_2$, $-CF_3$ and $-OCF_3$,

R^{19} and R^{20} independently are hydrogen, $-OR^{23}$, $-NR^{23}R^{24}$, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower

alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, heteroaryl-lower alkenyl or heteroaryl-lower alkynyl, $-C(O)NR^{23}R^{24}$ or $-C(O)OR^{23}$,

in which the cycloalkyl, cycloalkenyl, heterocyclyl, aryl and heteroaryl rings may optionally be substituted with one or more substituents independently selected from halogen, lower alkyl, lower alkanoyl, -OH, $-CH_2OH$, $-NO_2$, -CN, -C(O)OH, -O-lower alkyl, $-C(O)OCH_3$, $-C(O)NH_2$, $-OCH_2C(O)NH_2$, $-NH_2$, $-N(CH_3)_2$, $-CH_2N(CH_3)_2$, $-SO_2NH_2$, $-OCHF_2$, $-CF_3$ and $-OCF_3$,

wherein R^{23} and R^{24} independently are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-lower alkyl, cycloalkyl-lower alkenyl, cycloalkyl-lower alkynyl, cycloalkenyl-lower alkyl, cycloalkenyl-lower alkenyl, cycloalkenyl-lower alkynyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkenyl, heterocyclyl-lower alkynyl, heteroaryl-lower alkyl, heteroaryl-lower alkenyl or heteroaryl-lower alkynyl, or R^{23} and R^{24} together with the nitrogen atom to which they are bound form a 3 to 8 membered heterocyclic ring optionally containing one or more further heteroatoms selected from nitrogen, oxygen and sulfur and optionally containing one or more double bonds,

in which the cycloalkyl, cycloalkenyl, heterocyclyl, aryl and heteroaryl rings may optionally be substituted with one or more substituents independently selected from halogen, lower alkyl, lower alkanoyl, -OH, $-CH_2OH$, $-NO_2$, -CN, -C(O)OH, -O-lower alkyl, $-C(O)OCH_3$, $-C(O)NH_2$, $-OCH_2C(O)NH_2$, $-NH_2$, $-N(CH_3)_2$, $-CH_2N(CH_3)_2$, $-SO_2NH_2$, $-OCHF_2$, $-CF_3$ and $-OCF_3$,

q is 1, 2 or 3,

s is 0, 1, 2 or 3,

or

A and B may be connected and together form a C_{2-3}-alkylene radical,

with the provisos that

when L represents a group wherein n or r is 0, A is not halogen, -CN or -NO_2, and

B1

when M represents a group wherein n or r is 0, B is not halogen, -CN or -NO_2,]

as well as any optical or geometric isomer or mixture of optical or geometric isomers, or any tautomeric form thereof [including mixtures of these] or a pharmaceutically acceptable salt thereof.

Claims 2-36 (Cancelled)

Claim 37 (Currently amended) A compound of claim 1 of [the general] formula (V):



(V)

Claims 38-51 (Cancelled)

Claim 52 (Currently amended) A pharmaceutical composition comprising [, as an active ingredient, at least one] a compound according to claim 1 together with [one or more] a pharmaceutically acceptable [carriers or excipients] carrier or excipient.

Claim 53 (Currently amended) A pharmaceutical composition according to claim 52 in unit dosage form, said composition comprising from about 0.05 mg to about 1000 mg[, preferably from about 0.1 mg to about 500 mg and especially preferred from about 0.5 mg to about 200 mg] of the compound.

Claims 54-64 (Cancelled)

Claim 65 (Currently amended) A method for the treatment [and/or prevention] of disorders or diseases wherein an activation of the human GLP-1 receptor is beneficial, [the] said method comprising administering to a subject in need thereof an effective amount of a compound according to claim 1.

Claim 66 (Currently amended) The method according to claim 65 wherein the effective amount of the compound is in the range of from about 0.05 mg to about 2000 mg[, preferably from about 0.1 mg to about 1000 mg and especially preferred from about 0.5 mg to about 500 mg] per day.

Claim 67 (New) A pharmaceutical composition according to claim 52 in unit dosage form, said composition comprising from about 0.1 mg to about 500 mg of the compound.

Claim 68 (New) A pharmaceutical composition according to claim 52 in unit dosage form, said composition comprising from about 0.5 mg to about 200 mg of the compound.

Claim 69 (New) The method according to claim 65 wherein the effective amount of the compound is in the range of from about 0.1 mg to about 1000 mg per day.

Claim 70 (New) The method according to claim 65 wherein the effective amount of the compound is in the range of from about 0.5 mg to about 500 mg per day.